Drug prices by committee: one way Biden could lower costs

New York Times

11 February 2021 - Many countries use independent review boards to balance innovation and profit.

The United States receives worthwhile innovation (and also some not so worthwhile innovation) as a result of its high drug prices.

But there is no consensus about what the “right” level of innovation should be, so it’s unclear how much to lower or raise prices.

Read New York Times article

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Medicine , US , Regulation , Pricing